Liraglutide

Introduction Overview

Generic Name

liraglutide

Brand Name

Saxenda, Victoza

Dosage Form

Pre-filled injection pens delivering doses subcutaneously

Drug Class

GLP-1 Agonists (Incretin Mimetics)

Pharmacokinetics

Absorption:
Liraglutide is administered subcutaneously and is rapidly absorbed after injection. Peak plasma concentrations are typically reached within 8 to 12 hours post-dose. The bioavailability of liraglutide following subcutaneous administration is approximately 55-60%. Absorption is consistent regardless of injection site (abdomen, thigh, or upper arm). Food intake does not affect the absorption kinetics significantly, allowing administration without regard to meals.

Distribution:
Liraglutide demonstrates a volume of distribution of approximately 11-17 liters in adults, indicative of extensive distribution into extravascular tissues but limited penetration into erythrocytes or extensive binding to plasma proteins beyond albumin. Liraglutide binds reversibly to plasma albumin (>98%), contributing to its prolonged duration of action by protecting it from immediate degradation and renal elimination. The high affinity for albumin leads to a slow distribution phase.

Metabolism:
Liraglutide is metabolized via endogenous peptidase enzymes that slowly degrade peptide bonds, similar to the metabolism of native GLP-1, but with a final half-life extended by structural modifications. It undergoes catabolism into amino acids and small peptides distributed into general protein metabolism pathways without involvement of cytochrome P450 enzymes, reducing risk of classic drug-drug interactions at metabolic level. Unlike native GLP-1, liraglutide's fatty acid side chain permits albumin binding and reduces DPP-4 enzyme susceptibility, extending half-life to about 13 hours.

Elimination:
The elimination of liraglutide occurs through general protein catabolic pathways after metabolism, primarily via renal excretion of metabolites. The clearance is approximately 1.2 L/hour. The half-life allows once-daily dosing. There is no evidence of significant biliary excretion or enterohepatic recirculation. In patients with renal impairment, liraglutide pharmacokinetics appear unchanged or only minimally altered, but caution is advised to prevent dehydration-related worsening of kidney function due to side effects like nausea and vomiting. Hepatic impairment has not shown significant effects on liraglutide elimination, but clinical discretion is advised.

Dosage Forms

Available Dosage Forms:
- Saxenda: 3 mL pre-filled pen with liraglutide concentration 6 mg/mL, delivering doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg per injection.
- Victoza: 3 mL pre-filled pen with liraglutide concentration 6 mg/mL, delivering doses of 0.6 mg, 1.2 mg, and 1.8 mg.
- Generic liraglutide injection (Hikma Pharmaceuticals PLC): 3 mL pre-filled pen with liraglutide concentration 6 mg/mL, delivering doses of 0.6 mg, 1.2 mg, and 1.8 mg.

Dosages for Adults and Adolescents:
- Type 2 Diabetes (Victoza, Generic):
-- Initial dose: 0.6 mg subcutaneously once daily for one week (to reduce GI side effects)
-- Titrate to 1.2 mg daily; if additional control needed, increase to 1.8 mg daily.
-- Maintenance dose range: 1.2 mg to 1.8 mg daily; maximum dose 1.8 mg daily.
- Type 2 Diabetes (Children 10 years and older):
-- Same titration schedule as adults (start at 0.6 mg daily, titrate up to 1.8 mg daily).
- Weight Loss (Saxenda) in adults and children aged 12 and older:
-- Initiate at 0.6 mg once daily, increase weekly in 0.6 mg increments to reach 3 mg daily by week 5.
-- Dosage schedule:
Week 1: 0.6 mg daily
Week 2: 1.2 mg daily
Week 3: 1.8 mg daily
Week 4: 2.4 mg daily
Week 5: 3 mg daily (maintenance)
-- Children 12 and older who cannot tolerate 3 mg may reduce maintenance dose to 2.4 mg daily.

Specific Patient Populations:
- Renal impairment: No dosage adjustment recommended but careful monitoring advised due to dehydration risk.
- Hepatic impairment: Use caution; no specific dosage adjustments indicated.
- Pediatric use: Approved for type 2 diabetes in children aged 10 and older for glycemic control; approved for weight loss in obese children 12 to 17 years.
- Contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2).

Injection Technique and Storage:
- Inject subcutaneously in abdomen, thigh, or upper arm; rotate injection sites daily.
- Saxenda and Victoza pens should not be used interchangeably or together.
- Store unopened pens refrigerated between 2-8°C (36-46°F); do not freeze.
- After opening, pens can be stored at room temperature (15-30°C) or refrigerated for up to 30 days.

Mechanism Of Action

Liraglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the incretin hormone GLP-1 naturally produced in the intestine postprandially. Structurally analogous to endogenous GLP-1 but modified with a fatty acid side chain, liraglutide binds with high affinity to GLP-1 receptors located on pancreatic beta cells and various tissues, exerting its pharmacologic effects through activation of these receptors.

Upon binding, liraglutide stimulates insulin secretion in a glucose-dependent manner, enhancing insulin release only when blood glucose levels are elevated, thereby reducing the risk of hypoglycemia. It simultaneously inhibits glucagon secretion from pancreatic alpha cells, decreasing hepatic glucose production and lowering fasting and postprandial glucose levels. This dual regulation of insulin and glucagon contributes significantly to improved glycemic control in type 2 diabetes.

Additionally, liraglutide delays gastric emptying, slowing nutrient absorption and reducing postprandial glucose excursions. This action also contributes to early satiety and decreased appetite through central nervous system effects in the hypothalamus, particularly in regions governing appetite and food intake regulation. The appetite-suppressing mechanism underpins its use in weight management for obesity treatment.

Compared to native GLP-1, which is rapidly degraded by dipeptidyl peptidase-4 (DPP-4) enzymes, liraglutide's acylation and albumin binding enable prolonged activity with a half-life of approximately 13 hours, supporting once-daily subcutaneous dosing. Clinical studies have demonstrated liraglutide's efficacy to reduce cardiovascular risk in type 2 diabetes patients with established heart disease, likely due to improved metabolic parameters and direct vascular effects mediated through GLP-1 receptor pathways. Collectively, liraglutide's multi-faceted mechanisms render it a potent agent for improving glycemic control, facilitating weight loss, and reducing cardiovascular complications.

Pharmacological Actions

Agonist of GLP-1 (glucagon-like peptide-1) receptors, enhancing glucose-dependent insulin secretion.
Suppresses pancreatic glucagon secretion, reducing hepatic glucose output.
Slows gastric emptying, decreasing postprandial blood glucose spikes.
Reduces appetite via central nervous system pathways leading to decreased caloric intake.
Promotes weight loss through appetite suppression and delayed gastric emptying.
Improves beta cell function and sensitivity in diabetic patients.
Exerts cardioprotective effects, reducing risk of major cardiovascular events in type 2 diabetics.
Has a prolonged half-life due to albumin binding, enabling once-daily dosing.
Lowers HbA1c levels significantly when used as monotherapy or in combination.
Minimal risk of hypoglycemia when used alone due to glucose-dependent mechanism.
May influence lipid metabolism favorably by reducing triglycerides and LDL cholesterol.
Anti-inflammatory effects observed in vascular tissues in preclinical studies.
Modulates gastrointestinal motility contributing to sustained glycemic control.
Does not induce weight gain unlike some other antidiabetic agents.
Potential neuroprotective properties under investigation in dementia trials.

Therapeutic Or Clinical Uses

Improvement of blood sugar (glycemic) control in adults with type 2 diabetes mellitus.
Glycemic control in children aged 10 years and older with type 2 diabetes.
Reduction of major cardiovascular risk (heart attack, stroke, death) in adults with type 2 diabetes and established cardiovascular disease.
Chronic weight management in adults who are obese or overweight with weight-related comorbidities (Saxenda).
Weight loss therapy in pediatric patients aged 12 years and older with obesity.
Adjunct therapy alongside diet and exercise for type 2 diabetes management.
Potential investigational use in reducing alcohol use disorder by modulating reward pathways.
Off-label exploration in neurodegenerative diseases for possible neuroprotective benefits.
Treatment option when first-line oral agents are insufficient or contraindicated.
Use in patients where weight gain with other antidiabetic agents is undesirable.
As part of a comprehensive cardiovascular risk reduction strategy in diabetic patients.
Adjunct to improve beta-cell function and potentially delay disease progression.
Alternative for patients intolerant to other incretin-based therapies.
Contributes to gradual and sustained weight loss when combined with lifestyle modification.
May be considered in polypharmacy regimens to reduce insulin requirements.

Side Or Adverse Effects

Nausea, often mild and transient but may require dose adjustment or discontinuation.
Diarrhea and gastrointestinal discomfort including vomiting and constipation.
Decreased appetite leading to weight loss; can be excessive in rare cases.
Injection site reactions such as redness, itching, or swelling.
Fatigue and dizziness reported during dose titration or initial therapy.
Hypoglycemia especially when used concomitantly with insulin or sulfonylureas.
Headache and occasional malaise during early treatment phase.
Elevated pancreatic enzymes (lipase) without clinical pancreatitis signs.
Rare but serious pancreatitis; sudden persistent abdominal pain necessitates immediate evaluation.
Potential risk of thyroid C-cell tumors observed in rodents; clinical relevance uncertain.
Possible allergic reactions ranging from rash to anaphylaxis in rare cases.
Gallbladder-related adverse events including cholelithiasis and cholecystitis.
Fluid loss secondary to nausea/vomiting/diarrhea, potentially worsening renal function.
Mental health disturbances including depression, suicidal ideation, or mood changes.
Potential for injection technique-related issues such as lipodystrophy with improper rotation.

Precautions

Avoid use in patients with personal or family history of medullary thyroid carcinoma or MEN 2 syndrome.
Use caution in patients with a history of pancreatitis or pancreatic disease.
Monitor for signs of thyroid tumors, including neck swelling, difficulty swallowing, or hoarseness.
Careful dose titration recommended to mitigate gastrointestinal side effects.
Avoid concomitant use with other GLP-1 receptor agonists to prevent adverse interactions.
Not approved for type 1 diabetes or diabetic ketoacidosis treatment.
Be vigilant in patients with gastroparesis or severe gastrointestinal motility disorders.
Adjust concomitant anti-diabetic medications to reduce hypoglycemia risk.
Ensure proper patient education on injection techniques and site rotation.
Consider renal function monitoring due to risk of dehydration from GI side effects.
Evaluate mental health status periodically given reported mood and behavioral changes.
Avoid use during pregnancy unless benefits outweigh potential risks; insufficient data available.
Caution advised when used in breastfeeding women; clinical benefit versus risk must be assessed.
Discourage sharing of injection pens to prevent transmission of infections.
Inform patients about potential signs of allergic reactions requiring immediate attention.

Warnings

Black Box Warning for risk of thyroid C-cell tumors including medullary thyroid carcinoma observed in rodent studies, unknown relevance in humans.
Do not use liraglutide in patients with MED2 or personal/family history of medullary thyroid carcinoma.
Risk of acute pancreatitis; discontinue use immediately if symptoms such as severe persistent abdominal pain develop.
Potential for hypoglycemia, particularly when used with insulin or sulfonylureas; monitor blood glucose regularly.
Serious allergic reactions, including anaphylaxis and angioedema, may occur; seek emergency care if symptoms appear.
Can cause dehydration secondary to gastrointestinal adverse effects, which may exacerbate renal impairment.
Gallbladder adverse events including cholelithiasis and cholecystitis reported; promptly evaluate abdominal pain or jaundice.
Use caution when administering to patients undergoing anesthesia or deep sedation due to aspiration risk related to slowed gastric emptying.
Patients should be monitored for mental health changes including depression, anxiety, or suicidality.
Not suitable for treatment of type 1 diabetes or diabetic ketoacidosis.
Concomitant use with other GLP-1 receptor agonists is contraindicated due to lack of safety data.
Watch for symptoms indicative of thyroid neoplasm such as neck mass, dysphagia, or voice changes.
May cause injection site reactions; proper technique and site rotation mitigate risk.
Pregnant women should only use if potential benefit justifies the risk; breastfeeding safety is unknown.
Discontinue treatment if serious side effects develop or intolerable adverse reactions occur.

Contraindication

Known hypersensitivity to liraglutide or any components of the formulation.
Personal or family history of medullary thyroid carcinoma (MTC).
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Concomitant use with other GLP-1 receptor agonist medications.
Treatment of type 1 diabetes mellitus or diabetic ketoacidosis.
History of severe hypersensitivity reactions to liraglutide including anaphylaxis.
Patients with severe gastrointestinal disease such as gastroparesis.
Pregnant women, unless benefits outweigh risks (use only if clinically justified).
Known or suspected history of pancreatitis until clinically ruled out.
Pediatric patients under age 10 for type 2 diabetes or under age 12 for weight loss.
Patients with acute severe illness or acute pancreatitis.
Injections intended strictly for subcutaneous use; intravenous or intramuscular administration contraindicated.
Improper storage or use of expired product.
Patients unwilling or unable to comply with injection routines and monitoring.
Concomitant use with other drugs that prolong gastric emptying unless closely monitored.

Drug Interactions

Concurrent use with insulin or insulin secretagogues (e.g., sulfonylureas) may increase hypoglycemia risk; dose adjustments recommended.
Delayed gastric emptying caused by liraglutide may slow absorption of orally administered medications, potentially altering their onset and intensity.
No significant interactions with cytochrome P450 metabolic pathways noted.
Caution with medications requiring rapid gastrointestinal absorption such as analgesics or antibiotics.
Potential interaction with warfarin and other anticoagulants necessitating close monitoring of coagulation parameters.
No known significant interactions with commonly used cardiovascular drugs.
Hypoglycemia risk potentiated when used with alcohol or other hypoglycemic agents.
Concomitant use with other GLP-1 receptor agonists (e.g., semaglutide, dulaglutide) is contraindicated due to lack of safety and additive effect risks.
No significant interaction reported with oral contraceptives or hormone replacement therapies.
Medications influencing renal function may affect liraglutide safety profile indirectly through dehydration risks.
No major effects on QT interval or cardiac electrophysiology observed.
Drugs affecting gastrointestinal motility or pH may alter liraglutide's pharmacodynamic profile.
Limited data on herbal supplements interactions; caution advised.
Careful monitoring advised when initiating or discontinuing liraglutide with polypharmacy regimens.
Adjustment of doses for concomitant oral antidiabetic drugs may be necessary to prevent adverse effects.

Preparations Of The Drug

Saxenda: 3 mL pre-filled pen delivering liraglutide at 6 mg/mL concentration for weight loss indications, doses from 0.6 mg to 3 mg daily.
Victoza: 3 mL pre-filled pen containing liraglutide at 6 mg/mL concentration for type 2 diabetes treatment and cardiovascular risk reduction; available dose increments 0.6 mg, 1.2 mg, and 1.8 mg.
Generic liraglutide injection (Hikma Pharmaceuticals PLC): identical formulation to Victoza with liraglutide at 6 mg/mL in a 3 mL pre-filled pen delivering 0.6 mg,1.2 mg, and 1.8 mg doses for diabetes management.
All preparations include inactive ingredients such as disodium phosphate dihydrate, propylene glycol, phenol, and water for injection; pH adjusted with hydrochloric acid or sodium hydroxide as needed.
Pen devices are single-patient use and designed for subcutaneous injection only; include safety features preventing reuse of needles.
Storage recommendations specify refrigeration between 2-8°C prior to first use; pens usable at room temperature (15-30°C) for up to 30 days after opening.
Injection needles must be replaced with each use to prevent infection and maintain sterility.
User instructions provide detailed guidance on dose selection and self-injection techniques to ensure efficacy and safety.
Formulations are free from preservatives to reduce risk of adverse reactions.
Visible particulates or discoloration in solution contraindicate use of that dose/pen.
Proper disposal protocols for used pens and needles are outlined to prevent accidental injury or misuse.
Pens are designed to deliver fixed doses, enhancing dose accuracy and patient adherence.
Instructions highlight not to mix liraglutide with insulin in the same syringe to avoid dosing inaccuracies.
Single-patient use pens limit cross-patient contamination risks.
Patient support materials are available to facilitate correct storage, administration, and adherence.